OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
, , , y | 17 dic 2015
Acerca de este artículo
Publicado en línea: 17 dic 2015
Páginas: 1 - 7
Recibido: 18 sept 2015
Aceptado: 30 sept 2015
DOI: https://doi.org/10.1515/fco-2015-0014
Palabras clave
© 2015
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer